Table 2.
Determinants of metabolic acidosis and severe metabolic acidosis at month 3 posttransplant
| HCO3⁻ < 22 mmol/l |
HCO3⁻ ≤ 18 mmol/l |
|||
|---|---|---|---|---|
| Variable | Univariable: OR (95% CI); P value | Multivariable: OR (95% CI); P value | Univariable: OR (95% CI); P value | Multivariable: OR (95% CI); P value |
| Recipient age (yr) | 0.96 (0.94–0.98); P < 0.001 | 0.93 (0.91–0.96); P < 0.001 | 0.93 (0.89–0.98); P = 0.006 | 0.89 (0.84–0.95); P = 0.001 |
| Female sex | 1.14 (0.92–1.40); P = 0.223 | 1.31 (1.0–1.72); P = 0.048 | 1.65 (1.02–2.69); P = 0.041 | 2.15 (1.21–3.86); P = 0.010 |
| eGFR (ml/min per 1.73 m2) | 1.00 (0.99–1.00); P = 0.207 | 1.00 (0.99–1.00); P = 0.069 | 0.99 (0.98–1.00); P = 0.067 | 0.99 (0.98–1.00); P = 0.030 |
| Alkali supplementation (yes) | 2.02 (1.60–2.55); P < 0.001 | 1.40 (1.06–1.86); P = 0.020 | 2.56 (1.57–4.17); P < 0.001 | 2.34 (1.31–4.16); P = 0.004 |
| Allograft rejection (yes) | 1.26 (0.82–1.95); P = 0.287 | 1.16 (0.68–1.97); P = 0.581 | 0.99 (0.30–2.47); P = 0.988 | 0.56 (0.13–1.72); P = 0.310 |
| BMI Z-score | 0.98 (0.90–1.07); P = 0.673 | 0.97 (0.87–1.09); P = 0.651 | 0.92 (0.75–1.13); P = 0.398 | 0.88 (0.69–1.13); P = 0.567 |
| Decade of KTx (after 2010) | 1.37 (1.07–1.77); P = 0.014 | 1.06 (0.72–1.55); P = 0.779 | 1.19 (0.66–2.29); P = 0.584 | 1.47 (0.63–4.06); P = 0.410 |
| Tacrolimus predose concentration | 1.03 (0.98–1.08); P = 0.212 | 1.02 (0.97–1.08); P = 0.348 | 1.14 (1.05–1.24); P = 0.002 | 1.16 (1.06–1.27); P = 0.001 |
| Systolic BP Z-score | ||||
| Q2–Q3 | Reference | Reference | Reference | Reference |
| Q1 | 1.10 (0.76–1.58); P = 0.613 | 0.88 (0.57–1.34); P = 0.544 | 3.04 (1.36–7.01); P = 0.007 | 3.99 (1.64–10.08); P = 0.003 |
| Q4 | 0.82 (0.65–1.05); P = 0.113 | 0.81 (0.60–1.08); P = 0.150 | 1.59 (0.84–3.27); P = 0.175 | 1.93 (0.94–4.30); P = 0.087 |
| Time on dialysis | 1.01 (1.00–1.01); P = 0.002 | 1.00 (1.00–1.01); P = 0.245 | 1.01 (1.00–1.02); P = 0.044 | 1.01 (0.99–1.02); P = 0.274 |
| Primary diagnosis | ||||
| CAKUT | Reference | Reference | Reference | Reference |
| Glomerulopathy | 0.97 (0.75–1.25); P = 0.803 | 0.83 (0.60–1.14); P = 0.252 | 0.87 (0.45–1.59); P = 0.655 | 0.87 (0.42–1.75); P = 0.708 |
| Tubulointerstitial disease | 0.73 (0.55–0.97); P = 0.028 | 0.62 (0.44–0.87); P = 0.007 | 1.10 (0.58–2.00); P = 0.758 | 1.13 (0.53–2.32); P = 0.738 |
| HUS | 0.94 (0.56–1.55); P = 0.799 | 1.03 (0.54–1.95); P = 0.935 | 0.61 (0.10–2.07); P = 0.505 | 0.84 (0.13–3.14); P = 0.819 |
| Other or unknown | 0.62 (0.38–1.00); P = 0.055 | 0.52 (0.27–0.94); P = 0.035 | 0.77 (0.18–2.22); P = 0.673 | 1.27 (0.28–4.07); P = 0.714 |
| Donor source (living related) | 0.64 (0.51–0.80); P <0.001 | 0.69 (0.52–0.91); P = 0.009 | 0.55 (0.29–0.96); P = 0.047 | 0.85 (0.42–1.64); P = 0.638 |
BMI, body mass index; BP, blood pressure; CAKUT, congenital anomalies of the kidney and urinary tract; CI, confidence interval; eGFR, estimated glomerular filtration rate; HUS, hemolytic uremic syndrome; KTx, kidney transplantation; OR, odds ratio; Q quartile (Q1 denotes the lowest BP Z-score).